AI in Precision Medicine Market Size to Reach USD 25.46 Billion by 2035 as AI-Powered Clinical Decision Support Transforms Personalized Healthcare

Overview
According to DataM Intelligence, the AI in precision medicine market was valued at USD 2.76 billion in 2025 and is projected to reach USD 25.46 billion by 2035, growing at a CAGR of 24.88% during the forecast period from 2026 to 2035. The rapid adoption of artificial intelligence across healthcare is changing how diseases are diagnosed, treated, and monitored.
Healthcare providers are increasingly using AI to analyze genomic information, electronic health records, medical imaging, and clinical data to develop personalized treatment plans. Growing investments in precision oncology, biomarker discovery, and drug development are accelerating market expansion as hospitals, pharmaceutical companies, and research organizations seek faster and more accurate clinical decision-making.
Get More About This Market Research Report: https://www.datamintelligence.com/research-report/ai-in-precision-medicine-market?akash

Recent Developments
• June 2026 - Tempus AI
Tempus AI expanded its precision medicine platform by enhancing multimodal AI models, genomic analytics, and clinical decision support capabilities to improve personalized oncology treatment and biomarker identification.
• June 2026 - Microsoft
Microsoft strengthened its healthcare AI portfolio by expanding cloud-based AI infrastructure, secure health data integration, and generative AI technologies for genomic research and precision medicine applications.
• May 2026 - NVIDIA
NVIDIA introduced next-generation accelerated computing platforms and foundation AI models designed to support genomics, medical imaging, drug discovery, and precision medicine research.

Mergers & Acquisitions
• June 2026 - Tempus AI
Tempus AI expanded strategic collaborations with healthcare providers and research organizations to strengthen AI-powered precision medicine solutions and accelerate personalized oncology programs.
• May 2026 - Microsoft
Microsoft broadened partnerships across the healthcare ecosystem to improve cloud-based AI infrastructure and secure clinical data integration for precision medicine initiatives.
• May 2026 - NVIDIA
NVIDIA expanded collaborations with pharmaceutical companies and life science organizations to accelerate AI-driven genomics, medical imaging, and drug discovery workflows.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/ai-in-precision-medicine-market?akash

AI in Precision Medicine Market Segmentation
By Technology
• Deep Learning
• Querying Method
• Natural Language Processing (NLP)
• Context-Aware Processing
Deep learning and NLP are driving AI adoption by enabling faster analysis of genomic data, medical imaging, and clinical records. Context-aware processing further improves patient-specific diagnosis and treatment planning.
By Component
• Hardware
• Software
• Services
Software holds the largest share as AI platforms, analytics tools, and clinical decision support systems are central to precision medicine. Hardware and services support computing infrastructure, deployment, and integration.
By Application
• Oncology
• Cardiology
• Neurology
• Respiratory
• Others
Oncology remains the leading application due to the growing use of AI in biomarker discovery, genomic profiling, and personalized cancer treatment. AI adoption is also expanding across cardiology, neurology, and respiratory care.
By Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa
North America leads the market because of its advanced healthcare infrastructure and strong AI investments, while Asia-Pacific is the fastest-growing region driven by expanding genomics research, healthcare digitalization, and supportive government initiatives.

AI in Precision Medicine Market Competitive Landscape
Top 5 Key Players
• Microsoft Corporation
• NVIDIA Corporation
• Illumina Inc.
• Tempus AI
• IBM Corporation
Microsoft Corporation
Microsoft is strengthening its position in precision medicine through Azure cloud infrastructure, generative AI, and healthcare data platforms. The company works with hospitals, life sciences organizations, and research institutes to support genomic analysis, clinical decision support, and secure healthcare data management.
NVIDIA Corporation
NVIDIA provides the accelerated computing platforms that power AI-driven genomics, drug discovery, medical imaging, and large-scale healthcare analytics. Its GPUs and AI frameworks enable researchers to process complex molecular and clinical datasets more efficiently.
Illumina Inc.
Illumina is one of the leading companies in genomic sequencing and bioinformatics. By integrating AI-powered analytics with next-generation sequencing technologies, the company helps healthcare providers generate faster and more accurate genomic insights for personalized treatment decisions.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/ai-in-precision-medicine-market?akash

Regional Analysis
Europe represents one of the most promising markets for AI-powered precision medicine, supported by strong healthcare infrastructure, expanding genomics research, and increasing investments in digital healthcare. Although North America leads the global market, Europe continues to strengthen its position through collaborations between healthcare providers, research organizations, and technology companies.
Another major growth driver is Europe's focus on responsible AI deployment. Regulations such as the General Data Protection Regulation (GDPR) encourage healthcare organizations to develop secure and transparent AI solutions that protect sensitive patient information. While compliance requirements may lengthen implementation timelines, they also improve confidence among healthcare providers and patients, supporting long-term adoption.

Conclusion
The AI in precision medicine market is entering a period of rapid expansion as healthcare organizations increasingly rely on artificial intelligence to deliver personalized diagnosis and treatment. The ability to combine genomic data, medical imaging, electronic health records, and real-world clinical information is improving decision-making across oncology, cardiology, neurology, and several other therapeutic areas.
Advancements in machine learning, deep learning, and cloud computing are making AI solutions more accessible for hospitals, pharmaceutical companies, and research institutions. At the same time, growing investments in biomarker discovery, precision oncology, and AI-assisted drug development are creating new opportunities for technology providers and healthcare innovators.
Although challenges related to data privacy, cybersecurity, and regulatory compliance remain, continued technological innovation and strategic collaborations are expected to support sustained market growth. As healthcare systems continue shifting toward personalized medicine, AI will play an increasingly important role in improving patient outcomes, accelerating research, and transforming the future of clinical care.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=ai-in-precision-medicine-market?akash

Industry Related Reports:
Prostate Cancer Drugs Market Growth
The global Prostate Cancer Drugs Market reached USD 13.22 billion in 2024 and is expected to reach USD 28.10 billion by 2033, growing at a CAGR of 8.1% during 2025-2033. Market growth is supported by increasing prostate cancer incidence, expanding use of targeted therapies, and continued advances in oncology drug development.
Get More Insights: https://www.datamintelligence.com/research-report/prostate-cancer-drugs-market?akash

Tumor Microenvironment Targeted Oncology Therapies Market Share
The global Tumor Microenvironment Targeted Oncology Therapies Market reached USD 1.92 billion in 2025 and is expected to reach USD 5.11 billion by 2033, growing at a CAGR of 13% during 2026-2033. Rising demand for next-generation immunotherapies and targeted cancer treatments is driving growth in this market.
Get More Insights: https://www.datamintelligence.com/research-report/tumor-microenvironment-targeted-oncology-therapies-market?akash

Get More Japan Market Insights: https://www.datamintelligence.com/jp-market-research-report?akash

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.